Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REVIVE: AMDC-GIR for Tongue Dysphagia in Head and Neck Cancer
NCT05421689Phase 2Active, not recruiting
- Sponsor
- University of California, Davis
- Start
- May 2022
- Primary completion
- Dec 2026
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in dysphagia comparing 150 x 10⁶ AMDC-GIR dosage with Placebo (2 arms). Primary endpoints: Adverse Events at 24 months and Anterior tongue pressure measured from Iowa Oral Performance Instrument (IOPI) at 24 months. Started May 2022; status: active, not recruiting.
02
Drugs
AMDC-USR
03
Conditions
dysphagia
Beyond the preview
Go deeper on NCT05421689.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05421689.